Tevimbra 100 mg concentrate for solution for infusion clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer - HARMONIA
This study compares two common breast cancer medicines, Kisqali and IBRANCE, for advanced hormone receptor-positive, HER2-negative or HER2-enriched breast cancer. It looks at how well they stop the cancer from growing and aims to see if one is better than the other.
For: Patients with advanced hormone receptor-positive/HER2- negative/HER2-Enriched breast cancerSpain · Portugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
SOLTI-1904: EfficACy of tislelizumab and spartalizumab acROss multiPle cancer-types in patients with PD1-high mRNA expressing tumOrs defined by a singLe and pre-specIfied cutoff (ACROPOLI trial)
This study, called ACROPOLI, is testing new treatments for advanced cancer that has spread. It focuses on how well these treatments shrink tumours in patients whose cancers have a specific genetic marker. The main goal is to see if the treatments work, and how they affect patients' lives.
For: Metastatic diseaseSpain - AuthorisedPhase I and Phase II (Integrated)- Other
Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer
This study is looking at a new combination of treatments for advanced lung cancer. It combines a new drug called OMTX705 with standard chemotherapy and another modern treatment to see how safe and effective it is for patients whose cancer has spread.
For: Advanced/Metastatic Non-squamous Non-Small Cell Lung CancerSpain